Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Abstract

Lactobacillus delbrueckii ssp. lactis CRL 581, a thermophilic lactic acid bacterium used as a starter culture for the manufacture of several fermented dairy products, possesses an efficient proteolytic system that is able to release a series of potentially bioactive peptides (i.e., antihypertensive and phosphopeptides) from α- and β-caseins. Considering the potential beneficial health effects of the peptides released by L. delbrueckii ssp. lactis CRL 581 from milk proteins, the aim of this work was to analyze the anti-mutagenic and anti-inflammatory properties of the casein hydrolysates generated by the cell envelope-associated proteinase of this bacterium. The ability of α- and β-casein hydrolysates to suppress the mutagenesis of a direct-acting mutagen 4-nitroquinoline-N-oxide on Salmonella typhimurium TA 98 and TA 100 increased concomitantly with the time of casein hydrolysis. The anti-inflammatory effect of the β-casein hydrolysate was evaluated using a trinitrobenzene sulfonic acid (TNBS)-induced Crohn's disease murine model. The hydrolysate was administered to mice 10 d before the intrarectal inoculation of TNBS. The mice that received β-casein hydrolysate previously to TNBS showed decreased mortality rates, faster recovery of initial body weight loss, less microbial translocation to the liver, decreased β-glucuronidase and myeloperoxidase activities in the gut, and decreased colonic macroscopic and microscopic damage compared with the animals that did not receive this hydrolysate. In addition, β-casein hydrolysate exerted a beneficial effect on acute intestinal inflammation by increased interleukin 10 and decreased IFN-γ production in the gut. Our findings are consistent with the health-promoting attributes of the milk products fermented by L. delbrueckii ssp. lactis CRL 581 and open up new opportunities for developing novel functional foods.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus delbrueckiiFaster Recovery of Body WeightBeneficial
Moderate
Lactobacillus delbrueckiiIncreased Interleukin-10 Production in the GutBeneficial
Moderate
Lactobacillus delbrueckiiReduced Gut IFN-γ ProductionBeneficial
Large
Lactobacillus delbrueckiiReduced Microbial TranslocationBeneficial
Moderate
Lactobacillus delbrueckiiReduced Mortality RateBeneficial
Moderate
Lactobacillus lactis LI-23Accelerated Weight Loss RecoveryBeneficial
Moderate
Lactobacillus lactis LI-23Improved Macroscopic Colonic DamageBeneficial
Moderate
Lactobacillus lactis LI-23Increased IL-10 ProductionBeneficial
Moderate
Lactobacillus lactis LI-23Reduced Beta-Glucuronidase ActivityBeneficial
Moderate
Lactobacillus lactis LI-23Reduced Colonic Microscopic DamageBeneficial
Moderate
Lactobacillus lactis LI-23Reduced Gut IFN-γ ProductionBeneficial
Large
Lactobacillus lactis LI-23Reduced Microbial Translocation to the LiverBeneficial
Moderate
Lactobacillus lactis LI-23Reduced Mortality RateBeneficial
Moderate
Lactobacillus lactis LI-23Reduced Myeloperoxidase ActivityBeneficial
Moderate
Lactobacillus lactis LLa61Faster Recovery of Body WeightBeneficial
Moderate
Lactobacillus lactis LLa61Increased IL-10 ProductionBeneficial
Moderate
Lactobacillus lactis LLa61Reduced Colonic Oxidative DamageBeneficial
Large
Lactobacillus lactis LLa61Reduced Interferon-Gamma ProductionBeneficial
Moderate
Lactobacillus lactis LLa61Reduced Microbial Translocation to the LiverBeneficial
Moderate
Lactobacillus lactis LLa61Reduced Mortality RateBeneficial
Moderate
Back to top